Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

62.52USD
20 Jul 2018
Change (% chg)

$0.01 (+0.02%)
Prev Close
$62.51
Open
$62.10
Day's High
$62.54
Day's Low
$62.09
Volume
2,880,928
Avg. Vol
3,341,735
52-wk High
$66.41
52-wk Low
$52.83

Select another date:

Thu, Jul 19 2018

Photo

Merck lowers prices of some drugs after Trump calls out industry

Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.

UPDATE 1-Merck lowers prices of some drugs after Trump calls out industry

July 19 Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.

Merck lowers prices of some drugs after Trump calls out industry

July 19 Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a little-used hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.

U.S. Supreme Court to hear Merck appeal over Fosamax suits

WASHINGTON The U.S. Supreme Court on Thursday agreed to hear Merck & Co's appeal of a lower court's ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

CORRECTED-UPDATE 1-U.S. Supreme Court to hear Merck appeal over Fosamax suits

WASHINGTON, June 28 The U.S. Supreme Court on Thursday agreed to hear Merck & Co's appeal of a lower court's ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

U.S. Supreme Court to hear Merck appeal over Fosamax suits

WASHINGTON, June 28 The U.S. Supreme Court on Thursday agreed to hear Merck & Co's appeal of a lower court's ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

AstraZeneca, Merck eye $1 billion boost from cancer drug success

LONDON AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

UPDATE 1-AstraZeneca, Merck eye $1 bln boost from cancer drug success

* Puts drug ahead of competition in PARP medicine race (Adds analyst reaction, sales forecasts)

AstraZeneca, Merck eye wider cancer drug use after study success

LONDON, June 27 AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

Novo's pioneering diabetes pill beats Victoza, Januvia in tests

COPENHAGEN Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck & Co's Januvia and its own best-selling injectable treatment Victoza in tests.

Select another date: